Lupin Receives Approval for Dapagliflozin Tablets in the US

Global pharma major Lupin Limited has announced that it has received approval from the US Food and Drug Administration (US FDA) for its Abbreviated New Drug Application for Dapagliflozin Tablets, 5 mg and 10 mg. The US FDA has approved Lupin’s Dapagliflozin Tablets as bioequivalent to Farxiga® for the indications in the approved labeling. Lupin Limited, headquartered in Mumbai, India, is a global pharmaceutical leader with products distributed in over 100 markets. The company specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients.